Why ESG matters when choosing a CDMO partner?
In today’s biopharmaceutical landscape, ESG is no longer viewed solely as a compliance or reporting requirement. Increasingly, it serves as an indicator of how effectively a CDMO manages risk, strengthens operational resilience, and delivers long-term value to its clients.
As outsourcing decisions become more strategic, biotech and pharmaceutical companies are looking beyond technical expertise and GMP compliance. They seek partners that can provide transparency, responsible governance, supply chain resilience, and predictable execution throughout the product lifecycle.
In this Expert Insight, Kamila Hrecka-Procińska, ESG Senior Manager at Rezon Bio, discusses how ESG principles support stronger client relationships and why sustainability, responsible governance, and business resilience are becoming important differentiators when selecting a biologics CDMO.
Watch the video to learn:
- Why ESG is becoming a key factor in CDMO selection
- How ESG supports risk management and business resilience
- What clients should look for beyond compliance and technical capabilities
- How responsible business practices contribute to trusted, long-term partnerships
Watch the video to discover how ESG is shaping the future of CDMO partnerships and why it matters for your biologics program.
